Patents by Inventor Yanfeng Zhang

Yanfeng Zhang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Crystalline forms of lesinurad and its sodium salt
    Patent number: 10351536
    Abstract: Novel crystalline forms of lesinurad and its sodium salt, processes for their preparation, pharmaceutical compositions comprising these new forms, and use of them for treating or delaying progression or onset of diseases or disorders related to activity of uric acid transporter 1 (URAT1) proteins are disclosed. These novel forms were characterized by X-ray powder diffraction, differential scanning calorimetry, and other techniques. They can be readily prepared and are suitable for preparation of solid dosage forms owing to their ease of handling and superior pharmacological properties.
    Type: Grant
    Filed: November 20, 2014
    Date of Patent: July 16, 2019
    Assignees: Crystal Pharmatech Co., Ltd., Suzhou Pengxu Pharmatech Co., Ltd.
    Inventors: Minhua Chen, Yanfeng Zhang, Chaohui Yang, Xiaoyu Zhang, Peng Wang, Pixu Li
  • Fixed bed gasifier and method of gasification of biomass using the same
    Patent number: 10336955
    Abstract: A gasifier, including a vertically disposed furnace body, a monitoring unit, and a microwave plasma generating device. The furnace body includes a material and fuel inlet, a syngas outlet, an oxygen/vapor inlet, and a slag outlet. The furnace body has a clearance zone in an upper part thereof and a fixed bed zone in a lower part thereof. The slag outlet is disposed at the bottom of the furnace body. The monitoring unit is disposed close to the syngas outlet. At least one microwave plasma generating device is disposed on the furnace body.
    Type: Grant
    Filed: June 25, 2014
    Date of Patent: July 2, 2019
    Assignee: WUHAN KAIDI GENERAL RESEARCH INSTITUTE OF ENGINEERING & TECHNOLOGY CO., LTD.
    Inventors: Yilong Chen, Yanfeng Zhang, Minggui Xia, Liang Zhang
  • Method and apparatus for using excess heat from power plant flue gas to dry biomass fuel
    Patent number: 10337733
    Abstract: A method for drying biomass fuel using waste heat of flue gas from a power plant. The method includes: 1) stepwise recovering, by multi-stage condensation, sensible heat of flue gas; stepwise heating air using the sensible heat, to yield first-stage dry air and second-stage dry air; 2) convectively drying and dehydrating biomass fuel using the first-stage dry air having a temperature of between 150 and 180° C.; 3) further convectively drying and dehydrating the biomass fuel using the second-stage dry air having a temperature of between 80 and 100° C.; and 4) drying and dehydrating the biomass fuel using the third-stage dry air having a temperature of less than or equal to 25° C.
    Type: Grant
    Filed: April 24, 2017
    Date of Patent: July 2, 2019
    Assignee: ZHONGYING CHANGJIANG INTERNATIONAL NEW ENERGY INVESTMENT CO., LTD.
    Inventors: Yilong Chen, Shuchuan Hu, Yanfeng Zhang
  • IRON-BASED CATALYST FOR FISCHER-TROPSCH SYNTHESIS, METHOD OF PREPARING THE SAME AND METHOD OF USING THE SAME
    Publication number: 20190193064
    Abstract: A catalyst, including silica and iron. The silica is in the form of a mesoporous spherical particle. The iron is in the form of nanoparticles evenly distributed and encapsulated in the silica. The particle size of the silica is between 140 and 160 nm, and the silica includes pores between 2 and 9 nm in diameter.
    Type: Application
    Filed: February 27, 2019
    Publication date: June 27, 2019
    Inventors: Li GUO, Jiangang CHEN, Yanfeng ZHANG, Jiaqi JIN, Youliang SHI, Shenke ZHENG, Yan GONG
  • Co-crystal of a CDK inhibitor and an MEK inhibitor and process of preparation thereof
    Patent number: 10323035
    Abstract: The present disclosure relates to novel co-crystals of a CDK inhibitor and an MEK inhibitor and the preparation methods thereof. Specifically, the present disclosure provides hydrates or anhydrates which are named as Form I, Form II and Form III. The novel co-crystals provided in the present disclosure have good stability, low hygroscopicity and high solubility, and have an important value for further optimization and development of the drug.
    Type: Grant
    Filed: April 1, 2016
    Date of Patent: June 18, 2019
    Assignee: Crystal Pharmatech Co., Ltd.
    Inventors: Minhua Chen, Yanfeng Zhang, Qiyue Liu, Nan Xia, Chaohui Yang, Xiaoyu Zhang
  • CRYSTALLINE FORMS OF JAK1-SELECTIVE INHIBITOR, PROCESSES FOR PREPARATION AND USE THEREOF
    Publication number: 20190177314
    Abstract: The present disclosure relates to crystalline forms of JAK1-selective inhibitor, process for preparation and use for prevention and/or treatment of diseases associated with JAK family. The crystalline forms of the present disclosure show favorable properties such as simple preparation process, good stability, low hygroscopicity and good mechanical stability.
    Type: Application
    Filed: August 3, 2017
    Publication date: June 13, 2019
    Inventors: Minhua Chen, Yanfeng Zhang, Cunbo Yang, Kai Liu, Xiaoyu Zhang
  • NEW CRYSTAL FORM OF SODIUM-GLUCOSE CO-TRANSPORTER INHIBITOR PROCESSES FOR PREPARATION AND USE THEREOF
    Publication number: 20190169219
    Abstract: The present disclosure relates to novel crystalline forms of a sodium-glucose co-transporter inhibitor drug (Sotagliflozin), processes for preparation and use thereof. The present disclosure also relates to pharmaceutical composition comprises novel crystalline forms of Sotagliflozin and use of novel crystalline forms and pharmaceutical composition of Sotagliflozin for preparing drugs for treating diseases. The crystalline forms provided by the present disclosure have advantages of good stability, relatively low hygroscopicity, suitability for process development and post-treatment, simple processes for preparation, low cost, and has significant value for future drug optimization and development.
    Type: Application
    Filed: May 25, 2017
    Publication date: June 6, 2019
    Applicant: CRYSTAL PHARMACEUTICAL (SUZHOU) CO., LTD.
    Inventors: Minhua CHEN, Yanfeng ZHANG, Po ZOU, Kai LIU, Xiaoyu ZHANG
  • Crystal form of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxole-5-yl)cyclopropane formamido)-3-methylpyridine-2-yl)benzoic acid and preparation method thereof
    Patent number: 10308641
    Abstract: The present disclosure provides crystalline form A of 3-(6-(1-(2, 2-difluorobenzo [d] [1, 3] dioxo-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid and process of preparation thereof. The crystalline form A has low hygroscopicity, good stability, is convenient to store. It has higher solubility than that of prior art and therefore plays an important role in further optimization and development of the drug.
    Type: Grant
    Filed: August 11, 2016
    Date of Patent: June 4, 2019
    Assignee: Crystal Pharmatech Co., Ltd.
    Inventors: Minhua Chen, Yanfeng Zhang, Kai Liu, Po Zou, Xiaoyu Zhang
  • METHOD AND SYSTEM FOR MATCHING MULTI-DIMENSIONAL DATA UNITS IN ELECTRONIC INFORMATION SYSTEM
    Publication number: 20190146924
    Abstract: A method and system for matching multi-dimensional data units in an electronic information system, the method comprising: arranging interface modules and cache modules on a front-end processing device, and one interface module and two or more cache modules forming a matching module (101); performing service processing for at least two dimensions on a remote device, and writing a processed multi-dimensional data unit into the cache module of the front-end processing device (102); and after the interface module receives a user request, determining dimension information corresponding to a current scene of the user request, inquiring a matched multi-dimensional data unit in the catch module of the matching module according to the dimension information, and sending the multi-dimensional data unit obtained by the query to an output module (103).
    Type: Application
    Filed: January 6, 2017
    Publication date: May 16, 2019
    Inventors: Hui Zhao, Jing Wang, Peng Liu, Yanfeng Zhang
  • Crystalline form A of obeticholic acid and preparation method thereof
    Patent number: 10273262
    Abstract: The present invention relates to crystalline Form A of obeticholic acid and the preparation method thereof. The present invention provides Form A having characteristic peaks at 2theta value of 4.9°±0.2°, 5.2°±0.2°, 9.9°±0.2°. The present invention provides a novel crystalline form of obeticholic acid, which has good stability, good processability and other favorable properties, and is suitable for storage and usage as a final product. In addition, the preparation method is simple, low cost, and has great value for the future optimization and development of obeticholic acid.
    Type: Grant
    Filed: December 30, 2015
    Date of Patent: April 30, 2019
    Assignee: Crystal Pharmatech Co., Ltd.
    Inventors: Minhua Chen, Yanfeng Zhang, Xiaojuan Diao, Xiaoyu Zhang
  • CRYSTALLINE FORM E OF TAFAMIDIS MEGLUMINE, PROCESS FOR PREPARATION AND USE THEREOF
    Publication number: 20190119226
    Abstract: The present disclosure relates to a novel crystalline form E of Tafamidis meglumine, process for preparation and use thereof. When compared with prior crystalline forms, the novel crystalline form of the present disclosure has the advantages of simple process and low hygroscopicity, which provides a new and better choice for the development of Tafamidis meglumine drug product and is of great significance.
    Type: Application
    Filed: May 5, 2017
    Publication date: April 25, 2019
    Inventors: Minhua Chen, Yanfeng Zhang, Jiaoyang Li, Xiaoyu Zhang
  • Iron-based catalyst, method for preparing the same, and method for producing alpha-olefins using the same
    Patent number: 10266776
    Abstract: A catalyst including between 50.0 and 99.8 percent by weight of iron, between 0 and 5.0 percent by weight of a first additive, between 0 and 10 percent by weight of a second additive, and a carrier. The first additive is ruthenium, platinum, copper, cobalt, zinc, or a metal oxide thereof. The second additive is lanthanum oxide, cerium oxide, magnesium oxide, aluminum oxide, silicon dioxide, potassium oxide, manganese oxide, or zirconium oxide.
    Type: Grant
    Filed: October 20, 2016
    Date of Patent: April 23, 2019
    Assignee: WUHAN KAIDI ENGINEERING TECHNOLOGY RESEARCH INSTITUTE CO., LTD.
    Inventors: Yilong Chen, Yanfeng Zhang, Jiangang Chen, Dechen Song, Juan Zhang, Taomei Sun
  • Crystaline forms of N-[6-(cis-2,6-dimethylmorpholine-4-yl)pyridine-3-yl]-2-Methyl-4?-(trifluoromethoxy) [1,1?-biphenyl]-3-Methanamide monophosphate, and process of preparation thereof
    Patent number: 10266523
    Abstract: The present disclosure relates to novel crystalline forms of N-[6-(cis-2,6-dimethylmorpholine-4-yl)pyridine-3-yl]-2-methyl-4?-(trifluoromethoxy) [1,1?-biphenyl]-3-carboxamide monophosphate, and process of preparation thereof. The crystalline form of the monophosphate of a compound of formula (I) has low hygroscopicity, is convenient to store, has better stability than that of diphosphonate in prior art, can avoid the risk of crystal transformation in the development and production of the drug. The preparation method is simple, has low cost, and has important value for further optimization and development of the drug.
    Type: Grant
    Filed: March 30, 2016
    Date of Patent: April 23, 2019
    Assignee: CRYSTAL PHARMATECH CO., LTD.
    Inventors: Minhua Chen, Yanfeng Zhang, Fei Lu, Xiaoyu Zhang
  • HYDROCHLORIDE SALT CRYSTAL OF DRUG FOR TREATING OR PREVENTING JAK-ASSOCIATED DISEASE AND PREPARATION METHOD THEREOF
    Publication number: 20190100519
    Abstract: The present disclosure disclosed crystalline forms of Filgotinib hydrochloride for treating or preventing JAK-associated diseases, and preparation methods, pharmaceutical compositions, and formulations thereof. The present disclosure also disclosed the use of crystalline forms of Filgotinib hydrochloride in the prevention and/or treatment of diseases associated with JAK family. In comparison to the known crystalline forms, the crystalline forms of the present disclosure show more favorable properties in terms of formulation engineering, such as higher stability under low water activity conditions, simplicity in the preparation process and/or higher solubility.
    Type: Application
    Filed: March 21, 2017
    Publication date: April 4, 2019
    Applicant: CRYSTAL PHARMATECH CO., LTD.
    Inventors: Minhua CHEN, Yanfeng ZHANG, Kai LIU, Xiaoyu ZHANG
  • Crystal form of neratinib maleate and preparation method therefor
    Patent number: 10246437
    Abstract: The present invention relates to novel crystalline forms of Neratinib maleate and the preparation method thereof. The novel crystalline forms of Neratinib maleate in the present invention have high solubility, good stability, good processability, easy post-treatment process and other favorable properties. The preparation method is simple, low cost, and has an important value for future optimization and development of the drug.
    Type: Grant
    Filed: January 8, 2016
    Date of Patent: April 2, 2019
    Assignee: Crystal Pharmatech Co., Ltd.
    Inventors: Minhua Chen, Yanfeng Zhang, Xiaojuan Diao, Xiaoyu Zhang
  • Crystal form of lenvatinib methanesulfonate salt and preparation method thereof
    Patent number: 10246418
    Abstract: The present disclosure relates to a novel crystalline form of lenvatinib mesylate and the preparation method thereof. The novel crystalline form of mesylate of the present disclosure can be used for treating invasive and differentiated thyroid cancer. The novel crystalline form of mesylate of the present disclosure has good solubility, stability, and remarkable purification effect in process. The preparation method of this novel crystalline form is simple, low cost, and has an important value for future optimization and development of the drug.
    Type: Grant
    Filed: June 8, 2016
    Date of Patent: April 2, 2019
    Assignee: Crystal Pharmatech Co., Ltd.
    Inventors: Minhua Chen, Yanfeng Zhang, Xiaojuan Diao, Xiaoyu Zhang
  • CRYSTALLINE FORM A OF 2-[(2R)-2-METHYL-2-PYRROLIDYL]-1H-BENZIMIDAZOLE-7-CARBOXAMIDE DIHYDROCHLORIDE AND PREPARATION METHOD THEREOF
    Publication number: 20190092756
    Abstract: Provided are a crystalline form A of 2-[(2R)-2-methyl-2-pyrrolidyl]-1H-benzimidazole-7-carboxamide dihydrochloride and the preparation method and use thereof. The X-ray powder diffraction pattern of crystalline form A shows characteristic peaks at 2theta values of 8.3°±0.2°, 26.7°±0.2°, 16.1°±0.2°. Crystalline form A, compared with the existing crystalline forms, has a surprisingly excellent solubility, mechanical and storage stabilities and particle size distribution, is a more ideal crystalline fotbnn compared with the prior art forms, better satisfies medicinal requirements, and plays an important role in future optimization and development of the drug.
    Type: Application
    Filed: March 8, 2017
    Publication date: March 28, 2019
    Inventors: Minhua Chen, Yanfeng Zhang, Kai Liu, Xiaoyu Zhang
  • Crystalline form of AHU377, preparation method and use thereof
    Patent number: 10233144
    Abstract: The present disclosure relates to a novel crystalline form of a compound of formula (I), preparation method and use thereof. The novel crystalline form in the present disclosure has good stability, low hygroscopicity, and remarkable purification effect in process. The novel crystalline form of the compound of formula (I) provided by the present disclosure can be used for the preparation of the drug for treating heart failure.
    Type: Grant
    Filed: March 18, 2016
    Date of Patent: March 19, 2019
    Assignee: Crystal Pharmatech Co., Ltd.
    Inventors: Minhua Chen, Yanfeng Zhang, Chaohui Yang, Shu Yu, Xiaoyu Zhang, Liang Zhang
  • Method and device for fischer-tropsch synthesis
    Patent number: 10221360
    Abstract: A method for Fischer-Tropsch synthesis, the method including: 1) gasifying a raw material to obtain a crude syngas including H2, CO and CO2; 2) electrolyzing a saturated NaCl solution using a chloralkali process to obtain a NaOH solution, Cl2 and H2; 3) removing the CO2 in the crude syngas using the NaOH solution obtained in 2) to obtain a pure syngas; and 4) insufflating the H2 obtained in 2) to the pure syngas to adjust a mole ratio of CO/H2 in the pure syngas, and then introducing the pure syngas for Fischer-Tropsch synthesis reaction. A device for Fischer-Tropsch synthesis includes a gasification device, an electrolyzer, a first gas washing device, and a Fischer-Tropsch synthesis reactor.
    Type: Grant
    Filed: December 4, 2017
    Date of Patent: March 5, 2019
    Assignee: WUHAN KAIDI ENGINEERING TECHNOLOGY RESEARCH INSTITUTE CO., LTD.
    Inventors: Daxiang Wang, Pingyu Kuai, Meng Li, Yanfeng Zhang
  • Catalyst for fischer-tropsch synthesis and method for preparing the same, and method for preparing modified molecular sieve carrier
    Patent number: 10220375
    Abstract: A catalyst, including a molecular sieve carrier and an active component. The active component includes: iron, manganese, copper, and a basic promoter potassium. The molecular sieve carrier is a cerium salt and/or praseodymium salt modified-aluminosilicate molecular sieve carrier and/or silica-rich molecular sieve carrier. A method for preparing a catalyst for Fischer-Tropsch synthesis, includes: 1) fully dissolving a ferric salt, a manganese salt, a copper salt, and an alkali or a salt containing potassium element in water to yield an aqueous solution, stirring and adding sodium lauryl sulfate to the aqueous solution, and continuing stirring to yield a uniform solution; and impregnating a modified molecular sieve in the uniform solution to yield a mixed solution; and 2) drying and calcining the mixed solution to yield the catalyst.
    Type: Grant
    Filed: October 26, 2015
    Date of Patent: March 5, 2019
    Assignee: WUHAN KAIDI ENGINEERING TECHNOLOGY RESEARCH INSTITUTE CO., LTD.
    Inventors: Weiguang Yang, Qianqian Liu, Dechen Song, Changyuan Li, Xiaodong Zhan, Jiaqi Jin, Yanfeng Zhang